CTOs on the Move

Agrinos

www.agrinos.com

 
Agrinos is a biological crop input provider committed to improving the productivity and sustainability of modern agriculture worldwide. Our products help farmers by providing increased crop yield and productivity, improved crop quality, enhanced efficiency of conventional fertilizer and a reduced environmental footprint.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.agrinos.com
  • 279 Cousteau Place Suite 100
    Davis, CA USA 95618
  • Phone: 888.706.9505

Executives

Name Title Contact Details

Similar Companies

Iomai Corporation

Iomai Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Magen BioSciences Inc

Magen BioSciences Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncology Care Associates

Oncology Care Associates is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Qvin

Take control of your health in the most natural way possible.

Arsanis Inc

Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.